AR and neoplasm: Androgen deprivation therapy (ADT) induces tumor regressions in the vast majority of patients with metastatic hormone‐sensitive prostate cancer (mHSPC) and treatment intensification with docetaxel and/or androgen receptor (AR) pathway targeting agents has improved overall survival in randomized phase 3 clinical trials [2].